RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 382.17 Thousand USD | -70.26% |
| 2021 | 1.28 Million USD | 132.87% |
| 2020 | 551.78 Thousand USD | -22.48% |
| 2019 | 711.76 Thousand USD | 153.26% |
| 2018 | 281.04 Thousand USD | 23.77% |
| 2017 | 227.07 Thousand USD | -73.67% |
| 2016 | 862.4 Thousand USD | 140.74% |
| 2015 | 358.22 Thousand USD | -62.26% |
| 2014 | 949.19 Thousand USD | 2121.37% |
| 2013 | 42.73 Thousand USD | -88.02% |
| 2012 | 356.62 Thousand USD | -7.03% |
| 2011 | 383.59 Thousand USD | -90.93% |
| 2010 | 4.22 Million USD | -7.76% |
| 2009 | 4.58 Million USD | -22.61% |
| 2008 | 5.92 Million USD | -31.31% |
| 2007 | 8.62 Million USD | -50.74% |
| 2006 | 17.5 Million USD | 126.57% |
| 2005 | 7.72 Million USD | 134.9% |
| 2004 | 3.28 Million USD | 196.31% |
| 2003 | 1.1 Million USD | 102.92% |
| 2002 | 546.93 Thousand USD | 340.9% |
| 2001 | 124.05 Thousand USD | -75.17% |
| 2000 | 499.65 Thousand USD | -46.41% |
| 1999 | 932.36 Thousand USD | 107.3% |
| 1998 | 449.76 Thousand USD | 525.91% |
| 1997 | 71.85 Thousand USD | -77.06% |
| 1996 | 313.26 Thousand USD | -73.84% |
| 1995 | 1.19 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 186.81 Thousand USD | -51.12% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q2 | 735.5 Thousand USD | -23.43% |
| 2022 FY | 382.17 Thousand USD | -70.26% |
| 2022 Q4 | 382.17 Thousand USD | -34.22% |
| 2022 Q1 | 960.52 Thousand USD | -25.25% |
| 2022 Q3 | 580.98 Thousand USD | -21.01% |
| 2021 Q3 | 1.59 Million USD | -24.5% |
| 2021 Q4 | 1.28 Million USD | -19.36% |
| 2021 FY | 1.28 Million USD | 132.87% |
| 2021 Q2 | 2.11 Million USD | 569.12% |
| 2021 Q1 | 315.44 Thousand USD | -42.83% |
| 2020 Q2 | 492.61 Thousand USD | -26.57% |
| 2020 Q1 | 670.89 Thousand USD | -5.74% |
| 2020 FY | 551.78 Thousand USD | -22.48% |
| 2020 Q4 | 551.78 Thousand USD | 96.82% |
| 2020 Q3 | 280.35 Thousand USD | -43.09% |
| 2019 FY | 711.76 Thousand USD | 153.26% |
| 2019 Q1 | 750.36 Thousand USD | 167.0% |
| 2019 Q2 | 1.26 Million USD | 68.41% |
| 2019 Q3 | 970.93 Thousand USD | -23.17% |
| 2019 Q4 | 711.76 Thousand USD | -26.69% |
| 2018 Q1 | 955.13 Thousand USD | 320.63% |
| 2018 FY | 281.04 Thousand USD | 23.77% |
| 2018 Q2 | 712.43 Thousand USD | -25.41% |
| 2018 Q3 | 442.48 Thousand USD | -37.89% |
| 2018 Q4 | 281.04 Thousand USD | -36.49% |
| 2017 FY | 227.07 Thousand USD | -73.67% |
| 2017 Q4 | 227.07 Thousand USD | 1.33% |
| 2017 Q3 | 224.09 Thousand USD | -22.86% |
| 2017 Q1 | 541.34 Thousand USD | -37.23% |
| 2017 Q2 | 290.52 Thousand USD | -46.33% |
| 2016 Q2 | 1.64 Million USD | 1349.81% |
| 2016 Q1 | 113.75 Thousand USD | -68.25% |
| 2016 Q4 | 862.4 Thousand USD | -28.24% |
| 2016 FY | 862.4 Thousand USD | 140.74% |
| 2016 Q3 | 1.2 Million USD | -27.13% |
| 2015 FY | 358.22 Thousand USD | -62.26% |
| 2015 Q2 | 636.27 Thousand USD | -43.79% |
| 2015 Q1 | 1.13 Million USD | 19.26% |
| 2015 Q4 | 358.22 Thousand USD | -49.63% |
| 2015 Q3 | 711.23 Thousand USD | 11.78% |
| 2014 Q3 | 1.32 Million USD | 73.33% |
| 2014 FY | 949.19 Thousand USD | 2121.37% |
| 2014 Q4 | 949.19 Thousand USD | -28.19% |
| 2014 Q2 | 762.62 Thousand USD | -43.86% |
| 2014 Q1 | 1.35 Million USD | 3079.34% |
| 2013 Q3 | 202.41 Thousand USD | 675.45% |
| 2013 Q1 | 262.6 Thousand USD | -26.36% |
| 2013 FY | 42.73 Thousand USD | -88.02% |
| 2013 Q2 | 26.1 Thousand USD | -90.06% |
| 2013 Q4 | 42.73 Thousand USD | -78.89% |
| 2012 Q4 | 356.62 Thousand USD | 227.29% |
| 2012 FY | 356.62 Thousand USD | -7.03% |
| 2012 Q3 | 108.96 Thousand USD | -64.65% |
| 2012 Q1 | 285.95 Thousand USD | -25.45% |
| 2012 Q2 | 308.28 Thousand USD | 7.81% |
| 2011 Q3 | 652.68 Thousand USD | -78.48% |
| 2011 Q4 | 383.59 Thousand USD | -41.23% |
| 2011 FY | 383.59 Thousand USD | -90.93% |
| 2011 Q1 | 4.16 Million USD | -1.45% |
| 2011 Q2 | 3.03 Million USD | -27.22% |
| 2010 Q1 | 3.45 Million USD | -24.61% |
| 2010 Q4 | 4.22 Million USD | -24.71% |
| 2010 Q2 | 6.81 Million USD | 97.22% |
| 2010 Q3 | 5.61 Million USD | -17.61% |
| 2010 FY | 4.22 Million USD | -7.76% |
| 2009 Q3 | 1.39 Million USD | -54.11% |
| 2009 FY | 4.58 Million USD | -22.61% |
| 2009 Q4 | 4.58 Million USD | 229.03% |
| 2009 Q2 | 3.03 Million USD | -25.86% |
| 2009 Q1 | 4.09 Million USD | -30.86% |
| 2008 Q2 | 7.96 Million USD | -22.62% |
| 2008 Q1 | 10.29 Million USD | 19.46% |
| 2008 FY | 5.92 Million USD | -31.31% |
| 2008 Q4 | 5.92 Million USD | 3.33% |
| 2008 Q3 | 5.73 Million USD | -28.08% |
| 2007 Q4 | 8.62 Million USD | -18.69% |
| 2007 FY | 8.62 Million USD | -50.74% |
| 2007 Q2 | 12.29 Million USD | -16.03% |
| 2007 Q3 | 10.6 Million USD | -13.79% |
| 2007 Q1 | 14.64 Million USD | -16.31% |
| 2006 Q3 | 9.65 Million USD | -15.46% |
| 2006 Q4 | 17.5 Million USD | 81.32% |
| 2006 FY | 17.5 Million USD | 126.57% |
| 2006 Q1 | 13.45 Million USD | 74.2% |
| 2006 Q2 | 11.41 Million USD | -15.16% |
| 2005 Q3 | 9.67 Million USD | 69.3% |
| 2005 Q4 | 7.72 Million USD | -20.15% |
| 2005 Q2 | 5.71 Million USD | -15.55% |
| 2005 Q1 | 6.76 Million USD | 105.75% |
| 2005 FY | 7.72 Million USD | 134.9% |
| 2004 Q4 | 3.28 Million USD | 29.0% |
| 2004 FY | 3.28 Million USD | 196.31% |
| 2004 Q3 | 2.54 Million USD | 39.59% |
| 2004 Q2 | 1.82 Million USD | -19.74% |
| 2004 Q1 | 2.27 Million USD | 105.03% |
| 2003 Q3 | 1.52 Million USD | -24.63% |
| 2003 Q4 | 1.1 Million USD | -27.24% |
| 2003 Q1 | 355.31 Thousand USD | -35.03% |
| 2003 Q2 | 2.02 Million USD | 469.57% |
| 2003 FY | 1.1 Million USD | 102.92% |
| 2002 FY | 546.93 Thousand USD | 340.9% |
| 2002 Q4 | 546.93 Thousand USD | -38.71% |
| 2002 Q3 | 892.36 Thousand USD | -25.99% |
| 2002 Q2 | 1.2 Million USD | -27.75% |
| 2002 Q1 | 1.66 Million USD | 1245.38% |
| 2001 FY | 124.05 Thousand USD | -75.17% |
| 2001 Q4 | 124.05 Thousand USD | -40.68% |
| 2001 Q3 | 209.11 Thousand USD | -30.7% |
| 2001 Q2 | 301.76 Thousand USD | -30.09% |
| 2001 Q1 | 431.62 Thousand USD | -13.61% |
| 2000 Q2 | 1.25 Million USD | -16.66% |
| 2000 FY | 499.65 Thousand USD | -46.41% |
| 2000 Q1 | 1.5 Million USD | 61.81% |
| 2000 Q3 | 1.02 Million USD | -18.23% |
| 2000 Q4 | 499.65 Thousand USD | -51.39% |
| 1999 FY | 932.36 Thousand USD | 107.3% |
| 1999 Q4 | 932.36 Thousand USD | 0.0% |
| 1998 Q1 | 80 Thousand USD | 14.29% |
| 1998 FY | 449.76 Thousand USD | 525.91% |
| 1998 Q4 | 450 Thousand USD | 0.0% |
| 1998 Q2 | 30 Thousand USD | -62.5% |
| 1997 Q1 | 240 Thousand USD | -22.58% |
| 1997 Q3 | 100 Thousand USD | -16.67% |
| 1997 Q4 | 70 Thousand USD | -30.0% |
| 1997 Q2 | 120 Thousand USD | -50.0% |
| 1997 FY | 71.85 Thousand USD | -77.06% |
| 1996 Q3 | 260 Thousand USD | 13.04% |
| 1996 Q1 | 560 Thousand USD | 0.0% |
| 1996 Q2 | 230 Thousand USD | -58.93% |
| 1996 FY | 313.26 Thousand USD | -73.84% |
| 1996 Q4 | 310 Thousand USD | 19.23% |
| 1995 FY | 1.19 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -16444.459% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 80.483% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 96.379% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 30.78% |
| Rebus Holdings, Inc. | 5000.00 USD | -7543.54% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.706% |
| Qrons Inc. | 420.00 USD | -90894.524% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 50.408% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.632% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 20.472% |
| Skye Bioscience, Inc. | 11.94 Million USD | 96.799% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.016% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 94.707% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -400.533% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.643% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 73.312% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -428.124% |
| Mesoblast Limited | 667.9 Million USD | 99.943% |
| Marizyme, Inc. | 22.01 Million USD | 98.264% |
| Genus plc | 1.02 Billion USD | 99.963% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 71.865% |
| Pharming Group N.V. | 462.85 Million USD | 99.917% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 88.464% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 23.417% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 39.047% |
| ContraFect Corporation | 20.67 Million USD | 98.152% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 2.098% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 31.33 Million USD | 98.78% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 90.782% |
| MultiCell Technologies, Inc. | 126.22 USD | -302686.405% |
| ONE Bio Corp. | 70.08 Million USD | 99.455% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 59.329% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.703% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 11.474% |
| Q BioMed Inc. | 3.51 Million USD | 89.129% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.914% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -46.273% |
| Biomind Labs Inc. | 73.81 Thousand USD | -417.722% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.914% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 73.622% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.727% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 86.084% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 44.409% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 85.319% |
| GB Sciences, Inc. | 103.44 Thousand USD | -269.46% |
| Alpha Cognition Inc. | 2.45 Million USD | 84.415% |
| HST Global, Inc. | 1526.00 USD | -24944.364% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 61.317% |
| Halberd Corporation | 10.13 Thousand USD | -3672.352% |
| Enzolytics Inc. | 361.7 Million USD | 99.894% |
| Agentix Corp. | 261.39 Thousand USD | -46.208% |
| Resverlogix Corp. | 8.11 Million USD | 95.29% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 79.648% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.992% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.199% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 40.253% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1577.613% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 95.729% |
| AVAX Technologies, Inc. | 7.37 Million USD | 94.819% |
| Zenith Capital Corp. | 7410.00 USD | -5057.584% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.989% |
| Ember Therapeutics, Inc. | 184.00 USD | -207604.891% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -18.76% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -46.224% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 58.815% |
| Kadimastem Ltd | 2.3 Million USD | 83.413% |
| Helix BioMedix, Inc. | 3.02 Million USD | 87.366% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.275% |
| BioStem Technologies, Inc. | 14.56 Million USD | 97.375% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -569.382% |
| LadRx Corporation | 2.3 Million USD | 83.44% |
| Cell Source, Inc. | 195.17 Thousand USD | -95.816% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -8.077% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -8.077% |
| NovAccess Global Inc. | 62.24 Thousand USD | -513.959% |
| Affymax, Inc. | 7.44 Million USD | 94.865% |
| Itoco Inc. | 1.4 Million USD | 72.703% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -299.529% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -260.544% |
| Mobile Lads Corp. | 52.00 USD | -734855.769% |
| CytoDyn Inc. | 11.13 Million USD | 96.568% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -167.309% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2037.455% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 0.855% |
| SYBLEU INC | 330.46 Thousand USD | -15.647% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 6.655% |
| International Stem Cell Corporation | 5.39 Million USD | 92.91% |
| Bioxytran, Inc. | 137.63 Thousand USD | -177.668% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 97.452% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 97.695% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -383.768% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 55.801% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 94.916% |
| Neutra Corp. | 2851.00 USD | -13305.016% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.821% |
| PureTech Health plc | 693.97 Million USD | 99.945% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 95.265% |
| IXICO plc | 15.84 Million USD | 97.588% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 95.385% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.63% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.886% |